Kahn Brothers Group Inc. DE cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the 3rd quarter, Holdings Channel reports. The firm owned 309,537 shares of the medical equipment provider’s stock after selling 30,165 shares during the period. Hologic makes up 2.0% of Kahn Brothers Group Inc. DE’s holdings, making the stock its 15th largest holding. Kahn Brothers Group Inc. DE’s holdings in Hologic were worth $15,629,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Strs Ohio increased its stake in Hologic by 0.4% in the third quarter. Strs Ohio now owns 57,598 shares of the medical equipment provider’s stock valued at $2,908,000 after acquiring an additional 204 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of Hologic by 1.0% during the second quarter. Raymond James Trust N.A. now owns 21,950 shares of the medical equipment provider’s stock worth $1,054,000 after purchasing an additional 219 shares during the period. Advisory Services Network LLC lifted its holdings in shares of Hologic by 12.2% during the second quarter. Advisory Services Network LLC now owns 2,028 shares of the medical equipment provider’s stock worth $97,000 after purchasing an additional 220 shares during the period. Allianz Asset Management GmbH lifted its holdings in shares of Hologic by 1.6% during the second quarter. Allianz Asset Management GmbH now owns 16,584 shares of the medical equipment provider’s stock worth $796,000 after purchasing an additional 264 shares during the period. Finally, Hartford Investment Management Co. lifted its holdings in shares of Hologic by 1.0% during the second quarter. Hartford Investment Management Co. now owns 29,736 shares of the medical equipment provider’s stock worth $1,428,000 after purchasing an additional 291 shares during the period. 95.33% of the stock is currently owned by institutional investors.
A number of analysts recently commented on HOLX shares. Canaccord Genuity restated a “hold” rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and set a $57.00 price target (up from $52.00) on shares of Hologic in a research note on Thursday, August 1st. TheStreet lowered shares of Hologic from a “b-” rating to a “c” rating in a report on Wednesday. Piper Jaffray Companies upped their target price on shares of Hologic from $49.00 to $59.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $51.48.
In other news, insider Peter J. Valenti III sold 7,766 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total value of $381,621.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.90% of the company’s stock.
Hologic stock traded up $0.36 during midday trading on Friday, reaching $46.56. 2,274,912 shares of the stock were exchanged, compared to its average volume of 1,801,817. The company’s fifty day moving average is $48.95 and its 200-day moving average is $47.99. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.11 and a current ratio of 1.57. The firm has a market cap of $12.86 billion, a PE ratio of 20.30, a PEG ratio of 2.03 and a beta of 0.76. Hologic, Inc. has a 52 week low of $37.48 and a 52 week high of $52.19.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.65. The business had revenue of $865.80 million for the quarter, compared to analyst estimates of $846.54 million. Hologic had a negative net margin of 0.89% and a positive return on equity of 27.95%. Hologic’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.58 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 2.64 earnings per share for the current fiscal year.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Article: What are retained earnings?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.